Edesa Biotech to Present at Guggenheim Healthcare Innovation Conference
Globe Newswire•04/11/2026•16:30 ET
0
Key Highlights
- ➤Edesa management to present at Guggenheim Healthcare Innovation Conference, November 9–11, 2026
- ➤CEO Par Nijhawan scheduled for November 9 fireside chat at 3:00 pm ET
- ➤EB06 is being developed as an anti-CXCL10 antibody for vitiligo
- ➤EB01 is a Phase 3-ready candidate for moderate-to-severe chronic allergic contact dermatitis
- ➤Paridiprubart is under evaluation in a U.S. government-funded ARDS platform study
TORONTO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced that management will participate in Guggenheim’s 3rd Annual Healthcare Innovation Conference, including a fireside chat and one-on-one investor meetings.
Dates: November 9–11, 2026 Location: Boston, Massachusetts Presenter: Par Nijhawan MD, FRCPC, AGAF, Chief Executive Officer Fireside Chat: Monday, November 9, 2026, at 3:00 pm ET
Get started
Create a free account to read the full story.